Aref Zribi
Department of Medical Oncology, Faculty of Medicine of Tunis, University of Tunis El Manar, Military Hospital of Tunis, Montfleury, Tunis, Tunisia
Sonia Ben Nasr
Department of Medical Oncology, Faculty of Medicine of Tunis, University of Tunis El Manar, Military Hospital of Tunis, Montfleury, Tunis, Tunisia
Aya Khemir
Department of Pathology, Faculty of Medicine of Tunis, University of Tunis El Manar, Military Hospital of Tunis, Montfleury, Tunis, Tunisia
Faten Gargouri
Department of Pathology, Faculty of Medicine of Tunis, University of Tunis El Manar, Military Hospital of Tunis, Montfleury, Tunis, Tunisia
Ichrak Ben Abdallah
Department of Medical Oncology, Faculty of Medicine of Tunis, University of Tunis El Manar, Military Hospital of Tunis, Montfleury, Tunis, Tunisia
Issam Msakni
Department of Pathology, Faculty of Medicine of Tunis, University of Tunis El Manar, Military Hospital of Tunis, Montfleury, Tunis, Tunisia
Sana Fendri
Department of Medical Oncology, Faculty of Medicine of Tunis, University of Tunis El Manar, Military Hospital of Tunis, Montfleury, Tunis, Tunisia
Mehdi Balti
Department of Medical Oncology, Faculty of Medicine of Tunis, University of Tunis El Manar, Military Hospital of Tunis, Montfleury, Tunis, Tunisia
Basma Laabidi
Department of Pathology, Faculty of Medicine of Tunis, University of Tunis El Manar, Military Hospital of Tunis, Montfleury, Tunis, Tunisia
Abderrazek Haddaoui
Department of Medical Oncology, Faculty of Medicine of Tunis, University of Tunis El Manar, Military Hospital of Tunis, Montfleury, Tunis, Tunisia
Abstract
Chordoma is a rare malignant tumor of the spine. We report the case of a 26-year-old man who presented with facial paralysis and upper limbs paresthesia. Cerebral CT-scan and cerebro-spinal MRI revealed a 58mm locally advanced middle clival mass with deviation of median cerebral structures. Endoscopic biopsy concluded to a chondroid chordoma. Skeletal survey and thoraco-abdomino-pelvic CT-scan were normal. Treatment consisted in complete surgical removal of the tumor followed by adjuvant radiotherapy. The patient is alive free of disease with a follow up of 12 months.